This portion of our website contains archival information. Archived information should be considered accurate only as of the date listed next to the event. Archived information may be superseded by more recent information we have disclosed in later presentations, press releases, filings with the Securities and Exchange Commission or otherwise. Archived information may contain forward-looking statements. Actual results may materially differ based on several factors, including those described in the archived information, press releases and our filings with the SEC.
2010 | 2009 | 2008 | 2007 | 2006 |
- December 10, 2009
Targacept Initiates Phase 2 Study of TC-5619 in Cognitive Dysfunction in Schizophrenia - December 03, 2009
Targacept to Host Conference Call Today at 10:00 AM to discuss AstraZeneca Collaboration on TC-5214 for Major Depressive Disorder - December 03, 2009
AstraZeneca and Targacept Form Global Collaboration and License Agreement for Late-stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder - November 16, 2009
Targacept Added to NASDAQ Biotechnology Index - November 11, 2009
Targacept to Present at the Lazard Capital Markets 6th Annual Healthcare Conference - November 05, 2009
Targacept Reports Third Quarter 2009 Financial Results - October 29, 2009
Targacept to Report Third Quarter Financial Results on November 5, 2009 - October 21, 2009
Targacept Announces Participation in Upcoming Conferences - October 15, 2009
Targacept Presents Data from Highly Successful Phase 2b Trial of TC-5214 as Augmentation Treatment for Major Depressive Disorder - October 08, 2009
Targacept Announces Pricing of Common Stock Offering - October 08, 2009
Targacept Announces Common Stock Offering - September 10, 2009
Data to be Presented on Multiple Targacept NNR Therapeutics at Society for Neuroscience Satellite Symposium - August 05, 2009
Targacept Reports Second Quarter 2009 Financial Results - July 29, 2009
Targacept to Report Second Quarter Financial Results on August 5, 2009 - July 23, 2009
Targacept Awarded Grant from Michael J. Fox Foundation to Conduct Research in the Treatment of Side Effects of Parkinson’s Disease Therapy - July 15, 2009
Targacept’s TC-5214 Achieves All Primary and Secondary Outcome Measures in Phase 2b Trial as Augmentation Treatment for Major Depressive Disorder - July 08, 2009
Targacept Announces Decision by AstraZeneca to Advance AZD3480 Program in ADHD - May 11, 2009
Targacept Reports First Quarter 2009 Financial Results - May 11, 2009
Targacept Announces Positive Top-Line Results from Phase II Study of AZD3480 in Adult ADHD - May 04, 2009
Targacept to Report First Quarter Financial Results on May 11, 2009 - April 23, 2009
Targacept Initiates Phase 2 Study of TC-5214 in Patients with Resistant Hypertension - March 11, 2009
Targacept Provides Update on TC-6499 and Pain Program in GlaxoSmithKline Alliance - February 12, 2009
Targacept Reports Fourth Quarter and 2008 Financial Results - February 05, 2009
Targacept to Report Fourth Quarter and 2008 Financial Results on February 12, 2009 - February 03, 2009
Targacept to Present at BIO CEO & Investor Conference